<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081063</url>
  </required_header>
  <id_info>
    <org_study_id>5210170</org_study_id>
    <nct_id>NCT05081063</nct_id>
  </id_info>
  <brief_title>Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients</brief_title>
  <official_title>Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult male patients brought to the emergency department as Level A trauma activations who are&#xD;
      receiving emergency blood transfusion.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
        1. Evaluate PRBC equivalents transfused in each group in the first 24 hours (Primary&#xD;
           outcome)&#xD;
&#xD;
        2. Evaluate total transfusion in each group in the first 24 hours (Secondary Outcome)&#xD;
           including breakdown by FFP equivalents, platelet units, and cryoprecipitate&#xD;
&#xD;
        3. Evaluate 6 hour, 24 hour, and hospital mortality (Secondary Outcome)&#xD;
&#xD;
        4. Evaluate ICU outcomes in each group&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the results from Cotton et al, median transfusion in the component therapy group was&#xD;
      6 PRBC in the first 24 hours and 4 PRBC equivalents in the whole blood group. The standard&#xD;
      deviation (estimated from the interquartile range) was approximately 4. Thus with an&#xD;
      expectation of alpha = 0.05 and expected power of 90% to detect a similar 2 unit difference&#xD;
      in transfusion volume, a sample size of 190 should be sufficient; thus projected sample size&#xD;
      of 200 should be more than adequate. Age range will be 18 years and older, and only males&#xD;
      will be included in the study. Expected racial/ethnic distribution will be approximately 60%&#xD;
      white, 15% black, 8% Asian, and 18% other race. No actual recruitment will be performed;&#xD;
      rather all qualifying patients will be included. Consent waiver is being requested.&#xD;
&#xD;
      b. Objectives&#xD;
&#xD;
        1. Evaluate PRBC equivalents transfused in each group in the first 24 hours (Primary&#xD;
           outcome)&#xD;
&#xD;
        2. Evaluate total transfusion in each group in the first 24 hours (Secondary Outcome)&#xD;
           including breakdown by FFP equivalents, platelet units, and cryoprecipitate&#xD;
&#xD;
        3. Evaluate 6 hour, 24 hour, and hospital mortality (Secondary Outcome)&#xD;
&#xD;
        4. Evaluate ICU outcomes in each group:&#xD;
&#xD;
      1. ICU length of stay 2. Ventilator days 3. SOFA score on day of ICU discharge 4. Presence of&#xD;
      ARDS 5. Presence of TRALI 6. Presence of DVT/PE 7. Necessity for Dialysis 8. Necessity for&#xD;
      Tracheostomy 9. Evaluate viscoelastic testing parameters in both groups when sent on arrival&#xD;
      in ICU&#xD;
&#xD;
      1. Percentage of patients with EXTEM clotting time &gt; 80 sec 2. Percentage of patients with&#xD;
      EXTEM amplitude at 10 min &lt; 40mm and FIBTEM amplitude at 10 min â‰¤ 10mm 3. Percentage of&#xD;
      patients with EXTEM amplitude at 10 min &lt; 40mm and FIBTEM amplitude at 10 min &gt; 10mm 4.&#xD;
      Percentage of patients with maximum thrombolysis &gt; 15% 5. Interval analyses to be performed&#xD;
      after 6 and 12 months with provision to continue the study out to 24 months.&#xD;
&#xD;
      1. Stopping rule: A statistically significant difference in hospital mortality at 6 months or&#xD;
      12 months&#xD;
&#xD;
        1. If in favor of LTOWB, consideration of trial termination and making LTOWB the primary&#xD;
           standard of care for all trauma patients receiving emergency transfusion except for&#xD;
           child-bearing age females (unless Rh immunoglobulin can be administered)&#xD;
&#xD;
        2. If in favor of component therapy, consideration of trial termination and making&#xD;
           component therapy the primary standard care for all trauma patients receiving emergency&#xD;
           transfusion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adult male patients brought to the emergency department as Level A trauma activations who are receiving emergency blood transfusion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pRBC equivalents transfused</measure>
    <time_frame>24 hours post ED admission</time_frame>
    <description>assessment of pRBC equivalents transfused in each arm, an increase in HGB by 1g/dl per unit transfused will be considered successful&#xD;
A blood draw of 5ml will be obtained and tested to assess HGB level. An increase in HGB by 1g/dl per unit transfused will be considered a successful result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Change between ED admission date and 24 hours post discharge</time_frame>
    <description>Assessment of mortality&#xD;
This is a composite measurement which includes the following in order to be assessed as pulseless with no respiratory drive or brain death:&#xD;
there is no evidence of arousal or awareness to maximal external stimuli&#xD;
pupils are fixed in a midsized or dilated position and non reactive to light&#xD;
corneal, oculocephalic and oculovestibular reflexes are absent&#xD;
There is no facial movement to noxious stimuli&#xD;
the gag reflex is absent to bilateral posterior pharyngeal stimuli&#xD;
the cough reflex is absent to deep tracheal suctioning&#xD;
there is no brain mediated motor response to noxious stimuli of the limbs&#xD;
spontaneous respirations are not observed when apnea test targets reach pH &lt;7.30 and PaCO2 &gt;60mmhg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hemorrhagic Shock</condition>
  <condition>Acute Blood Loss Anemia</condition>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Low Titer O+ Whole Blood</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Titer O+ Whole blood provided to Level A trauma patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Component Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Component Therapy of O+ pRBC and FFP dispatched to trauma bay for level A traumas</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Routine labs</intervention_name>
    <description>Routine labs will be performed with CBC, BMP, Fox screen, ROTEM viscoelastic test, PT/INR, PTT and venous lactate for standard of care for all patients.</description>
    <arm_group_label>Component Therapy</arm_group_label>
    <arm_group_label>Low Titer O+ Whole Blood</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all adult male patients brought into the emergency department as LEVEL A trauma&#xD;
             activations who are receiving emergency blood transfusions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients (specifically excluded due to risk of alloimmunization of Rh-negative&#xD;
             female patients of childbearing age against Rh-positive blood)&#xD;
&#xD;
          -  children&#xD;
&#xD;
          -  prisoners&#xD;
&#xD;
          -  all patients classified as dead upon arrival to the trauma bay&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anthony M Strada, MD</last_name>
    <phone>603-953-6795</phone>
    <email>tonymstrada@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaushik Mukherjee, MD</last_name>
    <phone>909-558-4877</phone>
    <email>kmukherjee@llu.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Williams J, Merutka N, Meyer D, Bai Y, Prater S, Cabrera R, Holcomb JB, Wade CE, Love JD, Cotton BA. Safety profile and impact of low-titer group O whole blood for emergency use in trauma. J Trauma Acute Care Surg. 2020 Jan;88(1):87-93. doi: 10.1097/TA.0000000000002498.</citation>
    <PMID>31464874</PMID>
  </reference>
  <reference>
    <citation>Murphy C, Silva de Leonardi N. The use of low-titer group O whole blood is independently associated with improved survival compared to component therapy in adults with severe traumatic hemorrhage. Transfusion. 2021 Apr;61(4):1341-1342. doi: 10.1111/trf.16266.</citation>
    <PMID>33831229</PMID>
  </reference>
  <reference>
    <citation>Seheult JN, Anto V, Alarcon LH, Sperry JL, Triulzi DJ, Yazer MH. Clinical outcomes among low-titer group O whole blood recipients compared to recipients of conventional components in civilian trauma resuscitation. Transfusion. 2018 Aug;58(8):1838-1845. doi: 10.1111/trf.14779. Epub 2018 Aug 30.</citation>
    <PMID>30160310</PMID>
  </reference>
  <reference>
    <citation>Hanna K, Bible L, Chehab M, Asmar S, Douglas M, Ditillo M, Castanon L, Tang A, Joseph B. Nationwide analysis of whole blood hemostatic resuscitation in civilian trauma. J Trauma Acute Care Surg. 2020 Aug;89(2):329-335. doi: 10.1097/TA.0000000000002753.</citation>
    <PMID>32744830</PMID>
  </reference>
  <reference>
    <citation>Cotton BA, Podbielski J, Camp E, Welch T, del Junco D, Bai Y, Hobbs R, Scroggins J, Hartwell B, Kozar RA, Wade CE, Holcomb JB; Early Whole Blood Investigators. A randomized controlled pilot trial of modified whole blood versus component therapy in severely injured patients requiring large volume transfusions. Ann Surg. 2013 Oct;258(4):527-32; discussion 532-3. doi: 10.1097/SLA.0b013e3182a4ffa0. Erratum in: Ann Surg. 2014 Jul;260(1):178.</citation>
    <PMID>23979267</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Kaushik Mukherjee</investigator_full_name>
    <investigator_title>Head of Surgery, Trauma Division</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Shock, Hemorrhagic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

